LogicBio Therapeutics (LOGC) – PRNewswire
-
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
-
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
-
LogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE
-
LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference
-
LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates
-
LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting
-
LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia
-
LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference
-
LogicBio Therapeutics to Present at Barclays Global Healthcare Conference
-
LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates
-
LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program
-
LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference
-
LogicBio Therapeutics Provides Business Updates
-
LogicBio Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones
-
LogicBio Therapeutics to Participate in Upcoming Investor Conferences
-
LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes in Two New Indications Using GeneRide™ Genome Editing Technology
-
LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
-
LogicBio Therapeutics to Present New GeneRide™ Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
-
LogicBio Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
-
LogicBio Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
LogicBio Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones
-
LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021
-
LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia
-
LogicBio Therapeutics to Participate in Upcoming Investor Conferences
-
LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments
-
LogicBio Therapeutics Reports First Quarter Year 2021 Financial Results and Provides Business Update
-
LogicBio Therapeutics Strengthens Management Team with Key Appointments
-
LogicBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
-
LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia
-
LogicBio Therapeutics Announces Research Collaboration with Daiichi Sankyo
-
LogicBio Therapeutics Announces Clinical and Corporate Updates
-
LogicBio Therapeutics Announces Strategic Collaboration and Option Agreement with CANbridge Pharmaceuticals Leveraging Gene Editing and Gene Delivery Platforms
-
LogicBio Therapeutics to Present at 2021 Redburn Gene Therapy Summit
-
LogicBio Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update
-
LogicBio Therapeutics to Present at Upcoming Investor Conferences
-
LogicBio Announces Extension Of Collaboration With Children's Medical Research Institute
-
LogicBio Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
-
Cecilia Jones Joins LogicBio Therapeutics as Chief Financial Officer
-
LogicBio Therapeutics names Daphne Karydas and Jeff Goater to Board of Directors
-
Horizon Technology Finance Provides Third Quarter 2019 Portfolio Update
Back to LOGC Stock Lookup